BURNING ROCK BIOTECH LIMITED

(BNR)
  Report
Delayed Nasdaq  -  05/13 04:00:00 pm EDT
3.320 USD   -5.68%
04:01aBurning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GL
04:00aBurning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
AQ
03/22BURNING ROCK BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Burning Rock Reaffirms 2021 Revenue Guidance of RMB500 Million

12/28/2021 | 08:05pm EDT

GUANGZHOU, China, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that, based on the latest operating trends, the Company expects its 2021 revenue to be at or slightly above RMB500 million.

The Company is pleased with the recent progress achieved, despite elevated COVID impact that has been ongoing since the beginning of November, including the first diagnosed Omicron case in China and increased lock-downs in December. Despite the COVID challenges, the Company’s overall business volumes in November and December increased compared to that of September and October. In-hospital testing volumes have continued to grow, with November and December volumes slightly higher than that of September and October, demonstrating resilience of this important commercial channel. Central-lab testing volumes also saw sequential improvement, supported in part by recent commercial launch and good initial market uptake of two licensed-in products, DetermaRx (a risk stratification test for early-stage lung cancer patients, further details of which can be found at https://ir.brbiotech.com/news-releases/news-release-details/burning-rock-announces-exclusive-licensing-risk-stratification/) and myChoice (an FDA approved test for homologous recombination deficiency, or HRD, further details of which can be found at https://ir.brbiotech.com/news-releases/news-release-details/burning-rock-announces-licensing-myriad-mychoicer-tumor-testing/).

The Company expects to discuss its fourth quarter results in further details at the time of its Q4 results announcement in March 2022.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of 1) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, 2) Global pharmaceutical services on biomarker detection and companion diagnostics developing, and 3) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. The Company is devoted to developing innovative and reliable NGS-based testing products and advancing oncology precision medicine solutions.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com


Primary Logo

Source: Burning Rock Biotech Limited

2021 GlobeNewswire, Inc., source Press Releases

All news about BURNING ROCK BIOTECH LIMITED
04:01aBurning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
GL
04:00aBurning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022
AQ
03/22BURNING ROCK BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results - Form ..
PU
03/22Burning Rock Biotech Limited Reports Earnings Results for the Full Year Ended December ..
CI
03/22TRANSCRIPT : Burning Rock Biotech Limited, Q4 2021 Earnings Call, Mar 22, 2022
CI
03/22Burning Rock Biotech's Q4 Loss Widens, Revenue Rises
MT
03/21BURNING ROCK BIOTECH : Q4 2021 Presentation Slides
PU
03/21Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/21Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results
GL
03/21Burning Rock Biotech Limited Provides Revenue Guidance for the Year 2022
CI
More news
Analyst Recommendations on BURNING ROCK BIOTECH LIMITED
More recommendations
Financials
Sales 2022 620 M 91,3 M 91,3 M
Net income 2022 -656 M -96,6 M -96,6 M
Net cash 2022 673 M 99,1 M 99,1 M
P/E ratio 2022 -3,62x
Yield 2022 -
Capitalization 2 371 M 349 M 349 M
EV / Sales 2022 2,74x
EV / Sales 2023 1,31x
Nbr of Employees 1 394
Free-Float 67,8%
Chart BURNING ROCK BIOTECH LIMITED
Duration : Period :
Burning Rock Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BURNING ROCK BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 22,54 CNY
Average target price 84,82 CNY
Spread / Average Target 276%
EPS Revisions
Managers and Directors
Yu Sheng Han Chairman & Chief Executive Officer
Leo Li Chief Financial Officer & Director
Zhi Hong Zhang Chief Technology Officer
Shao Kun Chuai Chief Technology Officer
Wendy Hayes Independent Director
Sector and Competitors